drugset

drugset / Trial / NCT03728296

A Study of Autologous Induced Islet Body With Type 1 Diabetes

NCT03728296 ↗

Phase 0 Unknown 20 enrolled Allife Medical Science and Technology Co., Ltd.

SequentialOpen-labelTreatment

Summary

This is a single centre、single arm、open-label study，to investigate the safety and efficacy of Autologous induced islet body With Type 1 diabetes

Timeline

Start: 2019-01
Primary completion: 2020-01
Completion: 2021-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	islet body	Cell therapy	—	—

Indications